chartexchange

Milestone Pharmaceuticals Reports Third Quarter 2026 Financial Results and Announces Cost-Efficiency Measures Designed to Extend Cash Runway Through AFib-RVR Phase 3 Data

GlobeNewswire Inc. | Nov 13, 2026 7:08 AM EST

Launch of CARDAMYST ® (etripamil) nasal spray marked by steady prescription growth, new prescriber expansion and improving commercial coverage

Read original article